肝癌患者血浆RASSF1A及p16基因异常甲基化检测

何青芳; 严冬; 王立新

doi:10.11847/zgggws2010-26-07-10

肝癌患者血浆RASSF1A及p16基因异常甲基化检测

Promoter hypermethylation of RASSF1A and p16 gene in plasma of patients with hepatocellular carcinoma

摘要

摘要: 目的探讨血浆RASSF1A基因(Ras association domain family 1 gene)和p16基因的启动子区异常甲基化与原发性肝癌关系。方法采用甲基化特异性PCR(MSP)法,对100例原发性肝癌(HCC)患者、30例乙肝患者、30例肝硬化患者和30名健康体检者血浆中RASSF1A和p16基因的启动子区异常甲基化状况进行检测。结果HCC患者血浆RASSF1A和p16基因异常甲基化检出率分别为38.0%(38/100)和65.0%(65/100),而乙肝患者、肝硬化患者和健康体检者均未检出,与HCC组比较,差异均有统计学意义(P=0.000);Logistic回归分析发现,患者年龄、性别、血浆甲胎蛋白(AFP)、HBsAg、p16基因(RASSF1A基因)甲基化状况等与血浆中RASSF1A基因(p16基因)异常甲基化检测结果无关(P>>0.05)。结论原发性肝癌患者血浆DNA中可检测到RASSF1A基因和p16基因的甲基化;RASSF1A基因和p16基因的甲基化检测对肝癌筛查有重要意义。

Abstract: ObjectiveTo explore the value of promoter hypermethylation of RASSF1A gene(Ras association domain family 1 gene)and p16 gene in the plasma of hepatocellular carcinoma(HCC)patients.MethodsThe promoter hypermethylation status of RASSF1A and p16 gene in plasma of 100 HCC patients,30 hepatitis B patients,30 hepatocirrhosis patients and 30 health persons was detected with methylatlon specific PCR(MSP).ResultsAberrant RASSF1A and p16 methylation was found in 38.0% (38/100)and 65.0% (65/100)of plasma DNA among HCC patients;no methylated RASSF1A or p16 was detected in plasma samples of hepatitis B patients,hepatocirrhosis patients,or health persons (P=0.000).Charaters of the patients including age,gender,level of alpha fetoprotein,status of HBsAg,and methylation of p16 or RASSF1A gene showed no corelation with promoter hypermethylation of RASSF1A or p16 gene(P>0.05).ConclusionPromoter hypermethylation of RASSF1A and p16 can be detected in plasma DNA among HCC patients.This detection is valuable in the screening of HCC.

HTML全文

参考文献(10)

施引文献

资源附件(0)